*This table does not include recommendations that have been removed. Table 5. Continued Section 2014 Recommendation Description of Change from 2011 Meschia et al Guidelines for the Primary Prevention of Stroke 3805 Writing Group Disclosures Writing Group Member Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other James F. Meschia Mayo Clinic NINDS None None None None None None Cheryl Bushnell Wake Forest University Baptist Medical Center World Federation of Neurology None None None None None None Bernadette Boden-Albala New York University, Global Institute of Public Health NIH None None None None None None Lynne T. Braun Rush University Medical Center NIH None None None None Nurse Practitioner Advisory Board*; UpToDate* None Dawn M. Bravata Department of Veteran Affairs Department of Veteran Affairs ; NIH/NHLBI None None None None None None Seemant Chaturvedi University of Miami Miller School of Medicine None None None None None Abbott Vascular*; Boehringer-Ingelheim*; Thornhill Research* W.L. Gore* None Mark A. Creager Brigham and Women s Hospital Medtronic ; NIH None None None None AstraZeneca ; Baxter Healthcare*; Merck (via TIMI Group)*; Novartis*; Takeda* None Robert H. Eckel University of Colorado at Denver None None None None None Amarin*; Amylin*; Genetech*; Janssen, Johnson & Johnson*; Lilly*; Novo Nordisk*; Regulus*; Sanofi-Aventis* None Mitchell S.V. 